FDA Priority Review Voucher Redemption Fee Set At $4.6 Million In Fiscal 2011
This article was originally published in The Pink Sheet Daily
Executive Summary
Users of the voucher, designed as an incentive for developing therapies for tropical diseases, will pay the fee on top of the standard $1.5 million PDUFA user fee.
You may also be interested in...
Priority Review Voucher Value Still Confounds, But Remains An Incentive For Sponsors
As FDA increases the asking price, a survey by non-profit finds companies would expect to invest an average of $100 million to obtain a voucher, but responders gave a wide range of potential amounts.
Priority Review Voucher Value Still Confounds, But Remains An Incentive For Sponsors
As FDA increases the asking price, a survey by non-profit finds companies would expect to invest an average of $100 million to obtain a voucher, but responders gave a wide range of potential amounts.
Big Pharma More Willing To Cooperate On Neglected Disease Research But Funding Models Still Unclear
HONG KONG - Debate over how best to fund research and development of neglected diseases may be reshaped by changing patterns of cooperation among Big Pharma and non-industry groups